Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy

Immune aplastic anemia (iAA) frequently results in transfusion dependence on platelets and packed red blood cells, increasing the risk for complications. The most common immune-mediated cause for platelet-transfusion refractoriness is alloimmunization with HLA antibody (Ab) to nonself class I antigens. The clinical impact of the HLA alloimmunization has not been well studied in patients with iAA. We investigated the clinical relevance of HLA alloimmunization in our large cohort of patients with iAA from 5 prospective trials and correlated with disease outcomes. Of 444 patients with severe AA treated with immunosuppressive therapy (IST), 99 (22%) had HLA alloimmunization. The presence of HLA Ab was associated with shorter overall survival, reduced responses to IST and higher risk of clonal evolution. Our data suggest that HLA alloimmunization is a marker of disease outcome. Furthermore, using single-cell RNA sequencing, we show enhanced activation of both complement-mediated pathways and the adaptive immune system in alloimmunized patients, indicating an interconnection between immune compartments.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-03-14
DOI
https://doi.org/10.1182/bloodadvances.2024015301
Primary Topic
Mast cells and histamine
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy

Willy A. Flegel, Leo Chen, J. David Glass, Shouguo Gao et al.
Blood Advances
Mast cells and histamine
article

Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy

Willy A. Flegel, Leo Chen, J. David Glass, Shouguo Gao, Nuri Cha, Emma M. Groarke, Ruba Shalhoub, Neal S. Young, Jibran Durrani, Colin O. Wu, Xiaoyang Ma, Bhavisha A. Patel, Zhijie Wu, Olga Julia Rios, Jennifer Lotter, Valentina Baez
article en

Abstract

Immune aplastic anemia (iAA) frequently results in transfusion dependence on platelets and packed red blood cells, increasing the risk for complications. The most common immune-mediated cause for platelet-transfusion refractoriness is alloimmunization with HLA antibody (Ab) to nonself class I antigens. The clinical impact of the HLA alloimmunization has not been well studied in patients with iAA. We investigated the clinical relevance of HLA alloimmunization in our large cohort of patients with iAA from 5 prospective trials and correlated with disease outcomes. Of 444 patients with severe AA treated with immunosuppressive therapy (IST), 99 (22%) had HLA alloimmunization. The presence of HLA Ab was associated with shorter overall survival, reduced responses to IST and higher risk of clonal evolution. Our data suggest that HLA alloimmunization is a marker of disease outcome. Furthermore, using single-cell RNA sequencing, we show enhanced activation of both complement-mediated pathways and the adaptive immune system in alloimmunized patients, indicating an interconnection between immune compartments.

Blood AdvancesVol. 9(11)
National Institutes of Health (US), University of Miami (US), National Hospital (IN), National Heart, Lung, and Blood Institute (US), Center for Cancer and Blood Disorders (US), National Institutes of Health Clinical Center (US), Sylvester Comprehensive Cancer Center (US)
Good health and well-being
Openalex Percentile: Top 95%
Mast cells and histamine
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.